The Role of Amivantamab Plus Lazertinib for NSCLC
Panelists discuss how amivantamab, FDA approved for first-line treatment of advanced non–small cell lung cancer with specific EGFR mutations, can lead to significant infusion-related reactions, including serious cases that may require dose adjustments or discontinuation.
Video Player is loading.
Now Viewing
EP: 1.The Role of Amivantamab Plus Lazertinib for NSCLC
EP: 2.Treatment-Related IRRs for Patients on Amivantamab Plus Lazertinib
EP: 3.Updates on the SKIPPirr Trial
EP: 4.Prophylactic Management of IRRs With Amivantamab Plus Lazertinib for NSCLC
EP: 5.Key Takeaways and Clinical Pearls from SKIPPirr
Recent Videos
MonumenTAL-1: Implications of Talquetamab, Prior TCR, and Sequencing for R/R MM
Insights From MonumenTAL-1: Impressions of Updated Efficacy Outcomes
CEPHEUS Trial: Design/Baseline Characteristics
Introduction/Treatment Overview of Transplant-Ineligible Newly Diagnosed Multiple Myeloma
ASCO 2025: MonumenTAL-1 Extended Follow-Up for Talquetamab in R/R MM
Later R/R MM Treatment Landscape and Unmet Needs
COCOON in Practice: Patient Preparation, Key Insights, and Implementation Best Practices
Operational Considerations: Workflow Adjustments and Monitoring Systems for Effective COCOON Implementation
Building Support Systems: Resources and Multidisciplinary Collaboration for Optimizing COCOON Implementation
Measuring Impact: Observed Differences in Dermatologic AEs Between COCOON Protocol and Standard Approaches
Related Content
